## Thomas J Esparza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6505660/publications.pdf

Version: 2024-02-01

361413 552781 2,013 29 20 26 citations h-index g-index papers 32 32 32 3691 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Amyloid- $\hat{l}^2$ Dynamics Correlate with Neurological Status in the Injured Human Brain. Science, 2008, 321, 1221-1224.	12.6	270
2	Amyloidâ€beta oligomerization in Alzheimer dementia versus highâ€pathology controls. Annals of Neurology, 2013, 73, 104-119.	5.3	244
3	Molecular and Biochemical Characterization of a Cytokinin Oxidase from Maize. Plant Physiology, 2001, 125, 378-386.	4.8	195
4	Tau elevations in the brain extracellular space correlate with reduced amyloid- $\hat{l}^2$ levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain, 2012, 135, 1268-1280.	7.6	150
5	Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of $\hat{l}^2$ -amyloidosis. Neuron, 2017, 96, 1013-1023.e4.	8.1	134
6	Diversity of Amyloid-beta Proteoforms in the Alzheimer's Disease Brain. Scientific Reports, 2017, 7, 9520.	3.3	125
7	Soluble Amyloid-beta Aggregates from Human Alzheimer's Disease Brains. Scientific Reports, 2016, 6, 38187.	3.3	119
8	Immunological Reversal of Autoimmune Diabetes Without Hematopoietic Replacement of $\hat{A}$ Cells. Science, 2006, 311, 1778-1780.	12.6	103
9	High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme. Scientific Reports, 2020, 10, 22370.	3.3	95
10	Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. Journal of Neural Transmission, 2010, 117, 85-96.	2.8	87
11	Distinct Temporal and Anatomical Distributions of Amyloid- $\hat{l}^2$ and Tau Abnormalities following Controlled Cortical Impact in Transgenic Mice. PLoS ONE, 2011, 6, e25475.	2.5	80
12	Non-canonical soluble amyloid-beta aggregates and plaque buffering: controversies and future directions for target discovery in Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 62.	6.2	62
13	Traumatic brain injury reduces soluble extracellular amyloid- $\hat{l}^2$ in mice: A methodologically novel combined microdialysis-controlled cortical impact study. Neurobiology of Disease, 2010, 40, 555-564.	4.4	48
14	Quantitative assessments of traumatic axonal injury in human brain: concordance of microdialysis and advanced MRI. Brain, 2015, 138, 2263-2277.	7.6	45
15	Polarity of varicosity initiation in central neuron mechanosensation. Journal of Cell Biology, 2017, 216, 2179-2199.	5.2	44
16	Human Apolipoprotein E4 Worsens Acute Axonal Pathology but Not Amyloid-Î <sup>2</sup> Immunoreactivity After Traumatic Brain Injury in 3×TG-AD Mice. Journal of Neuropathology and Experimental Neurology, 2013, 72, 396-403.	1.7	36
17	Disease-Modifying Effects of M <sub>1</sub> Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. ACS Chemical Neuroscience, 2017, 8, 1177-1187.	3.5	36
18	Single-Domain Antibodies for the Detection of SARS-CoV-2 Nucleocapsid Protein. Analytical Chemistry, 2021, 93, 7283-7291.	6.5	30

#	Article	IF	CITATIONS
19	Prospective natural history study of <i>C9orf72</i> ALS clinical characteristics and biomarkers. Neurology, 2019, 93, e1605-e1617.	1.1	29
20	Activation of Type B T Cells after Protein Immunization Reveals Novel Pathways of In Vivo Presentation of Peptides. Journal of Immunology, 2007, 178, 122-133.	0.8	22
21	Repetitive Concussive and Subconcussive Injury in a Human Tau Mouse Model Results in Chronic Cognitive Dysfunction and Disruption of White Matter Tracts, But Not Tau Pathology. Journal of Neurotrauma, 2019, 36, 735-755.	3.4	19
22	Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological, and pathological disease in a Syrian hamster model of COVID-19. MAbs, 2022, 14, 2047144.	5.2	10
23	Soluble amyloid-beta buffering by plaques in Alzheimer disease dementia versus high-pathology controls. PLoS ONE, 2018, 13, e0200251.	2.5	9
24	Live Neuron High-Content Screening Reveals Synaptotoxic Activity in Alzheimer Mouse Model Homogenates. Scientific Reports, 2020, 10, 3412.	3.3	8
25	Pharmacokinetics of Single Domain Antibodies and Conjugated Nanoparticles Using a Hybrid near Infrared Method. International Journal of Molecular Sciences, 2021, 22, 8695.	4.1	8
26	Unbiased high-content screening reveals $\hat{Al^2}$ and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer $\hat{a} \in \mathbb{N}$ s patients and high-pathology controls. PLoS ONE, 2021, 16, e0259335.	2.5	2
27	P1â€099: Purification and Quantitative Characterization of Amyloidâ€Beta Oligomers from Alzheimer's Disease Brain Lysates. Alzheimer's and Dementia, 2016, 12, P439.	0.8	O
28	P1â€100: Amyloidâ€Beta (Aβ) Isoforms and Ptms of Soluble Aβ Oligomers from Human Brain. Alzheimer's and Dementia, 2016, 12, P439.	0.8	0
29	[P2–068]: SOLUBLE AMYLOIDâ€BETA AGGREGATES FROM HUMAN ALZHEIMER's DISEASE BRAINS. Alzheimer's and Dementia, 2017, 13, P631.	0.8	О